{ "model": { "rank": 5744, "code": "thing-q8285", "model_id": "vr.tr.myasthenia-gravis", "name": "myasthenia gravis", "purpose": "Enable an AI agent to represent evidence for myasthenia gravis, track its manifestations and course, and identify appropriate clinical review or emergency escalation.", "family": "Thing Registry", "category": "Information and virtual systems", "status": "research-draft", "kind": "thing", "plane": "INF", "domain": "INF.KNW", "industry": "", "version": "", "url": "/models/thing/q8285/", "tier": 2, "score": 65, "payload": { "layer": "wikidata", "aliases": [ "myasthenic crisis", "neonatal myasthenia gravis", "adult-onset myasthenia gravis", "juvenile myasthenia gravis", "myasthenia, limb-girdle, autoimmune" ], "aliasCount": 5, "merged": 5, "knownIn": 65, "facets": null, "markers": [], "lexicalClass": "", "senseRank": null, "alsoRegisteredAs": "vr.tr.myasthenia-gravis", "source": { "dataset": "wikidata", "item": "Q8285", "url": "https://www.wikidata.org/wiki/Q8285", "license": "CC0 1.0" } }, "research": { "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-07T09:11:50Z", "providers": [ "Codex" ], "missingProviders": [ "Grok" ], "pass": 2, "cost": { "grok": { "usd": null, "turns": null, "seconds": 8, "error": "Error: Internal error: {\n \"message\": \"API error (status 402 Payment Required): Grok Build usage balance exhausted\",\n \"http_status\": 402\n}", "retried": true }, "codex": { "seconds": 114.7, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.3\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a07b21-a1fe-7dc1-89d8-468c36f09073\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: myasthenia gravis\nRegistry id: vr.tr.myasthenia-gravis\nPlane / domain: INF / INF.KNW\nRegistry definition: (none recorded)\nNames folded into this entr" } } }, "metaModel": { "id": "THING-Q8285", "registryId": "vr.tr.myasthenia-gravis", "name": "myasthenia gravis", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "INF.KNW" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q8285/", "model": { "registry_id": "vr.tr.myasthenia-gravis", "name": "myasthenia gravis", "purpose": "Enable an AI agent to represent evidence for myasthenia gravis, track its manifestations and course, and identify appropriate clinical review or emergency escalation.", "definition": "", "scope_statement": "This model owns the recognition criteria, subtype distinctions, state assessments and action constraints for myasthenia gravis under vr.tr.myasthenia-gravis in INF/INF.KNW, linking individual clinical observations to the disease concept without treating the concept itself as a patient.", "in_scope": [ "Evidence supporting, contradicting or leaving uncertain an autoimmune myasthenia gravis diagnosis.", "Ocular and generalized manifestations, antibody phenotype and thymic associations.", "Fatigable weakness, functional burden and changes over time.", "Bulbar and respiratory deterioration, exacerbations and crisis history.", "MG-specific treatment response, medication cautions and clinical decision dependencies." ], "out_of_scope": [ "Complete patient identity, general medical history and encounter administration.", "Independent models of congenital myasthenic syndromes, Lambert-Eaton syndrome, botulism and other diagnostic alternatives.", "Thymoma staging, tumour biology and oncology treatment planning.", "Drug manufacture, complete prescribing information and procedural execution.", "Independent neonatal, pregnancy, infection and anaesthesia models, except their MG-specific relationships." ], "distinguishing_features": [ "Look for reproducible loss of muscle performance during sustained or repeated activity and recovery with rest; distinguish observed weakness from a report of tiredness alone. [MGFA diagnosis](https://myasthenia.org/understanding-mg/diagnosing-mg/)", "Evaluate AChR, MuSK and appropriately interpreted additional antibody results alongside the clinical pattern; negative tests do not independently exclude MG. [MGFA diagnosis](https://myasthenia.org/understanding-mg/diagnosing-mg/)", "Use repetitive nerve stimulation and single-fiber electromyography to assess neuromuscular transmission, with specialist interpretation rather than treating an abnormal result as a unique MG identifier. [MGFA diagnosis](https://myasthenia.org/understanding-mg/diagnosing-mg/)", "Distinguish autoimmune MG from inherited congenital myasthenic syndromes through mechanism, genetic evidence and history, and from transient neonatal weakness through maternal antibody exposure. [MGFA related disorders](https://myasthenia.org/understanding-mg/mg-related-disorders/)", "Distinguish the postsynaptic autoimmune process of MG from the presynaptic process of Lambert-Eaton syndrome using specialist diagnostic evidence. [MGFA related disorders](https://myasthenia.org/understanding-mg/mg-related-disorders/)" ], "characteristics": [ { "name": "Diagnostic standing", "kind": "state", "unit_or_values": "suspected | supported | clinician-confirmed | disputed | excluded; dated with assessor and evidence", "why_it_matters": "Prevents a provisional label from becoming an unquestioned diagnosis." }, { "name": "Distribution of weakness", "kind": "category", "unit_or_values": "ocular-only | generalized | uncertain, plus affected ocular, facial, bulbar, neck, limb and respiratory muscle groups", "why_it_matters": "Separates disease distribution from overall severity and records newly involved muscle groups." }, { "name": "Fatigability and recovery", "kind": "measurement", "unit_or_values": "task, repetitions or duration in seconds, observed performance change and recovery interval", "why_it_matters": "Makes activity-dependent weakness assessable across observations." }, { "name": "Antibody evidence", "kind": "category", "unit_or_values": "AChR, MuSK, LRP4 or other specified target; positive | negative | equivocal | not tested, with assay and laboratory interpretation", "why_it_matters": "Preserves subtype evidence and distinguishes seronegativity from incomplete testing." }, { "name": "Electrophysiological evidence", "kind": "measurement", "unit_or_values": "RNS decrement in percent; SFEMG jitter in microseconds and blocking where reported; muscle, protocol and reference limits", "why_it_matters": "Allows specialist findings to be evaluated in their testing context." }, { "name": "Daily functional burden", "kind": "measurement", "unit_or_values": "MG-ADL item scores and total 0-24, with date, respondent and assessment context", "why_it_matters": "Supports longitudinal comparison while preserving which activities account for change." }, { "name": "Clinical severity classification", "kind": "category", "unit_or_values": "MGFA class I-V with applicable subclasses, classification version, date and assessor", "why_it_matters": "Records a clinical severity assessment without substituting it for the full course. [MGFA outcome measures](https://onlinelibrary.wiley.com/doi/full/10.1002/mus.28417)" }, { "name": "Respiratory assessment", "kind": "measurement", "unit_or_values": "vital capacity in L and mL/kg; inspiratory pressure in cm H2O with sign convention; time, technique, reliability and support status", "why_it_matters": "Makes respiratory trends reviewable without asserting one universal intervention threshold." }, { "name": "Thymic association", "kind": "relation", "unit_or_values": "linked imaging, pathology and thymectomy records; suspected | established | not identified | not assessed", "why_it_matters": "Connects MG management to thymic findings while retaining their diagnostic provenance." }, { "name": "Course and treatment response", "kind": "state", "unit_or_values": "improving | stable | worsening | uncertain; clinician-assigned outcome category, treatment exposure and dated baseline", "why_it_matters": "Separates present symptoms, longitudinal change and treatment dependence." } ], "affordances": [ "Assemble a traceable MG evidence summary and identify missing or contradictory diagnostic information.", "Compare dated weakness distributions and functional assessments to flag possible generalization or deterioration.", "Flag reported breathing difficulty or rapidly worsening bulbar function for urgent human assessment using an established escalation pathway.", "Prepare medication and procedure caution reviews against current MG guidance for clinician or pharmacist assessment.", "Summarize treatment exposure, functional response and adverse effects for specialist review.", "Generate an MG-specific clinical handover with diagnostic uncertainty, crisis history and the current care plan." ] }, "sources": [], "structure": { "bundles": [ { "id": "diagnostic-recognition", "name": "Diagnostic recognition", "description": "Represent why a presentation is attributed to MG and what could overturn that attribution.", "rationale": "An MG label must remain distinguishable from symptoms, test abnormalities and competing diagnoses.", "layers": [ { "id": "clinical-pattern", "name": "Clinical pattern", "description": "Capture the observed pattern that prompted investigation for MG.", "findings": [ { "id": "demonstrated-fatigable-weakness", "name": "Demonstrated fatigable weakness", "description": "Record affected movements, activity dependence and recovery separately from subjective fatigue.", "questions": [ { "text": "Which movements weaken during sustained or repeated use, and what recovery follows rest?", "kind": "measurement", "id": "demonstrated-fatigable-weakness-q01" }, { "text": "Which observations were examined directly, reported by the person or inferred from earlier records?", "kind": "provenance", "id": "demonstrated-fatigable-weakness-q02" } ] } ] }, { "id": "diagnostic-adjudication", "name": "Diagnostic adjudication", "description": "Connect investigations and alternatives to the current diagnostic judgment.", "findings": [ { "id": "supporting-and-conflicting-tests", "name": "Supporting and conflicting tests", "description": "Retain original antibody and electrophysiology reports, test conditions and specialist interpretations.", "questions": [ { "text": "What were the antibody and electrophysiological results, methods, dates and laboratory reference limits?", "kind": "provenance", "id": "supporting-and-conflicting-tests-q01" }, { "text": "How did the diagnosing clinician reconcile negative, equivocal or discordant results?", "kind": "definition", "id": "supporting-and-conflicting-tests-q02" } ] }, { "id": "alternative-explanations", "name": "Alternative explanations", "description": "Keep competing explanations explicit until their relevance has been assessed.", "questions": [ { "text": "What evidence distinguishes this presentation from Lambert-Eaton syndrome, congenital myasthenic syndromes, botulism, myopathy or focal ocular disease?", "kind": "boundary", "id": "alternative-explanations-q01" }, { "text": "Which unresolved alternative requires additional specialist assessment before accepting MG?", "kind": "action", "id": "alternative-explanations-q02" } ] } ] } ] }, { "id": "phenotype-and-thymic-context", "name": "Phenotype and thymic context", "description": "Represent clinically meaningful MG subtypes and their supporting evidence.", "rationale": "Distribution, antibody findings and thymic associations create different clinical decision contexts.", "layers": [ { "id": "clinical-and-antibody-phenotype", "name": "Clinical and antibody phenotype", "description": "Maintain distribution and serological classification as separate, revisable assessments.", "findings": [ { "id": "phenotype-assignment", "name": "Phenotype assignment", "description": "Record current and historical weakness distribution alongside the exact antibody testing scope.", "questions": [ { "text": "Is weakness currently ocular-only or generalized, and has extraocular weakness ever been documented?", "kind": "boundary", "id": "phenotype-assignment-q01" }, { "text": "Which antibody targets and assays support the assigned phenotype, and which remain untested?", "kind": "provenance", "id": "phenotype-assignment-q02" }, { "text": "What definition of seronegative is being used in this assessment?", "kind": "definition", "id": "phenotype-assignment-q03" } ] } ] }, { "id": "thymic-and-onset-context", "name": "Thymic and onset context", "description": "Connect thymic evidence and circumstances of onset to the MG assessment.", "findings": [ { "id": "thymic-findings", "name": "Thymic findings", "description": "Link chest imaging and pathology without inferring a thymic diagnosis from the MG label.", "questions": [ { "text": "What imaging or pathology establishes the thymic assessment, and when was it performed?", "kind": "provenance", "id": "thymic-findings-q01" }, { "text": "Does the finding require a linked thymoma or surgical assessment?", "kind": "action", "id": "thymic-findings-q02" } ] }, { "id": "onset-mechanism", "name": "Onset mechanism", "description": "Record onset age, exposure timing and evidence relevant to autoimmune, inherited or passively transferred mechanisms.", "questions": [ { "text": "What is the earliest supported symptom onset relative to medication exposure and relevant family or maternal history?", "kind": "provenance", "id": "onset-mechanism-q01" }, { "text": "Does the evidence support autoimmune MG or a linked congenital or transient neonatal disorder?", "kind": "boundary", "id": "onset-mechanism-q02" } ] } ] } ] }, { "id": "functional-state-and-course", "name": "Functional state and course", "description": "Represent the impact and evolution of MG using dated, comparable observations.", "rationale": "A single examination or aggregate score cannot represent fluctuating weakness and its consequences.", "layers": [ { "id": "current-functional-impact", "name": "Current functional impact", "description": "Connect symptom distribution to activities and clinical assessments.", "findings": [ { "id": "activity-limitations", "name": "Activity limitations", "description": "Record which visual, speaking, chewing, swallowing, breathing and limb activities are affected.", "questions": [ { "text": "Which MG-ADL items or directly described activities are impaired, and by how much?", "kind": "measurement", "id": "activity-limitations-q01" }, { "text": "When was the assessment made relative to exertion, rest and medication dosing?", "kind": "provenance", "id": "activity-limitations-q02" }, { "text": "Which limitations may instead reflect another condition or a treatment adverse effect?", "kind": "boundary", "id": "activity-limitations-q03" } ] } ] }, { "id": "longitudinal-change", "name": "Longitudinal change", "description": "Distinguish within-day variation from sustained improvement, worsening or altered distribution.", "findings": [ { "id": "course-assessment", "name": "Course assessment", "description": "Preserve baseline, comparable follow-up observations and the definition behind each clinician-assigned outcome.", "questions": [ { "text": "Compared with which dated baseline has weakness, functional burden or muscle involvement changed?", "kind": "measurement", "id": "course-assessment-q01" }, { "text": "What criteria and treatment status support a label such as exacerbation, minimal manifestations or remission?", "kind": "definition", "id": "course-assessment-q02" }, { "text": "Does the change meet the person's agreed threshold for clinical reassessment?", "kind": "action", "id": "course-assessment-q03" } ] } ] } ] }, { "id": "bulbar-and-respiratory-safety", "name": "Bulbar and respiratory safety", "description": "Represent signs of airway, swallowing and ventilatory compromise and the corresponding escalation plan.", "rationale": "Respiratory deterioration can require immediate care; crisis must be distinguished from a general symptom flare. [MGFA emergencies](https://myasthenia.org/living-with-mg/mg-emergency-preparedness/mg-emergencies/)", "layers": [ { "id": "threatened-functions", "name": "Threatened functions", "description": "Track breathing and airway protection separately from overall symptom scores.", "findings": [ { "id": "bulbar-safety", "name": "Bulbar safety", "description": "Record swallowing, secretion handling, speech and cough changes with clinical assessments.", "questions": [ { "text": "Is there new choking, difficulty handling secretions, weak cough or rapidly worsening speech or swallowing?", "kind": "measurement", "id": "bulbar-safety-q01" }, { "text": "What swallowing or airway assessment and current feeding instructions have clinicians documented?", "kind": "provenance", "id": "bulbar-safety-q02" } ] }, { "id": "ventilatory-status", "name": "Ventilatory status", "description": "Retain respiratory symptoms, serial measurements, measurement reliability and assistance requirements.", "questions": [ { "text": "How have breathing symptoms, vital capacity and inspiratory pressure changed, with what measurement limitations?", "kind": "measurement", "id": "ventilatory-status-q01" }, { "text": "Is ventilatory assistance required, and what cause and urgency have clinicians assigned?", "kind": "definition", "id": "ventilatory-status-q02" } ] } ] }, { "id": "emergency-escalation", "name": "Emergency escalation", "description": "Connect observed deterioration to an explicit clinical response pathway.", "findings": [ { "id": "crisis-response-context", "name": "Crisis response context", "description": "Record prior crises, current clinician assessment and the emergency handover information needed for action.", "questions": [ { "text": "Which current signs require immediate emergency assessment under the applicable care pathway?", "kind": "action", "id": "crisis-response-context-q01" }, { "text": "What prior crisis, ventilation and rescue-treatment history should accompany escalation?", "kind": "provenance", "id": "crisis-response-context-q02" }, { "text": "Who receives the escalation, and how is receipt or clinical review confirmed?", "kind": "action", "id": "crisis-response-context-q03" } ] } ] } ] }, { "id": "treatment-response-and-action-constraints", "name": "Treatment response and action constraints", "description": "Connect MG interventions to their purpose, observed outcomes and requirements for clinical decisions.", "rationale": "The agent must distinguish a recorded treatment plan from evidence of benefit and from authority to change treatment.", "layers": [ { "id": "therapeutic-course", "name": "Therapeutic course", "description": "Track symptomatic treatment, immune treatment, rescue interventions and thymectomy in the clinical timeline.", "findings": [ { "id": "intervention-response", "name": "Intervention response", "description": "Link each intervention to its intended outcome, actual exposure, follow-up and adverse effects.", "questions": [ { "text": "What MG problem was each intervention intended to address, and what treatment was actually received?", "kind": "provenance", "id": "intervention-response-q01" }, { "text": "What functional or clinical change followed, over what interval and with which concurrent interventions?", "kind": "measurement", "id": "intervention-response-q02" }, { "text": "What evidence separates inadequate response from intolerance, interrupted access or incomplete exposure?", "kind": "boundary", "id": "intervention-response-q03" } ] } ] }, { "id": "decision-prerequisites", "name": "Decision prerequisites", "description": "Capture subtype, safety and contextual dependencies before a treatment or procedure is reconsidered.", "findings": [ { "id": "medication-and-exposure-cautions", "name": "Medication and exposure cautions", "description": "Check new exposures against current MG cautions while preserving the distinction between an association and an absolute prohibition. [MGFA cautionary drugs](https://myasthenia.org/understanding-mg/learn-more-about-mg-treatments/mg-brochures/cautionary-drugs/)", "questions": [ { "text": "Which medicines, supplements or recent exposure changes require MG-specific clinician or pharmacist review?", "kind": "action", "id": "medication-and-exposure-cautions-q01" }, { "text": "What evidence, exposure timing and alternative explanations support suspected medication-related worsening?", "kind": "provenance", "id": "medication-and-exposure-cautions-q02" } ] }, { "id": "clinical-action-authority", "name": "Clinical action authority", "description": "Represent the prerequisites and responsible clinician for MG treatment changes and coordination around surgery, pregnancy or infection.", "questions": [ { "text": "Which antibody phenotype, thymic finding, comorbidity or life circumstance affects the proposed decision?", "kind": "boundary", "id": "clinical-action-authority-q01" }, { "text": "Which current guideline, product information or local pathway governs eligibility and monitoring?", "kind": "provenance", "id": "clinical-action-authority-q02" }, { "text": "What may the agent summarize or flag, and which decision requires the treating clinician's authorization?", "kind": "action", "id": "clinical-action-authority-q03" } ] } ] } ] } ] }, "openQuestions": [ "Which diagnostic evidence standard and assay sequence should govern uncertain or seronegative presentations, particularly isolated ocular symptoms?", "Which assessment instruments, observation intervals and change thresholds should be adopted for children, adults and different MG phenotypes?", "Which locally approved escalation pathway should interpret respiratory trends and bulbar deterioration when measurements are missing or unreliable?", "Which current jurisdiction-specific treatment eligibility and monitoring requirements apply to each antibody phenotype and special clinical circumstance?", "Does the wider Vercy catalogue already contain a canonical MG model, and how should this entry link to transient neonatal myasthenia and treatment-associated MG without duplicating concepts?" ], "statistics": { "bundles": 5, "layers": 10, "findings": 14, "questions": 34 } }, "draft": { "generator": "vr.draft.v3", "status": "draft-generated", "researched": false, "archetype": "discipline or field of knowledge", "method": "Written from the archetype playbook - what this kind of thing needs beyond identity and provenance - and from the structure that recurred across 6,333 models already researched by two engines. Applied to this entry by rule. No source was read for this thing and no claim here is researched. This entry carries no facets of its own, so they were inferred from its domain - a guess about a whole domain applied to one thing.", "facetsInferred": true, "nextPass": "A researcher replaces this draft with a sourced specification. Treat every sentence below as a proposal to argue with.", "purpose": "Give an agent a durable, checkable way to recognise a myasthenia gravis, record what state it is in, and decide what may be done with it.", "whatItIs": "Enable an AI agent to represent evidence for myasthenia gravis, track its manifestations and course, and identify appropriate clinical review or emergency escalation.", "characteristics": { "substance": "information", "origin": "conceptual", "agency": "inert" }, "whatYouCanDoWithIt": [ "read and interpreted" ], "distinguishingFeatures": [ "Names folded into this entry, which a task may need to split apart again: myasthenic crisis, neonatal myasthenia gravis, adult-onset myasthenia gravis, juvenile myasthenia gravis, myasthenia, limb-girdle, autoimmune.", "5 finer distinctions are held as aliases rather than separate entries, because telling them apart needs a task that asks for it.", "Described in 65 Wikipedia languages, which is a measure of how widely the thing is known, not of how important it is." ], "openQuestionsForResearch": [ "Which of the bundles below does a real task actually need, and which are ceremony?", "What does this thing have that the facets do not capture at all?", "Which neighbouring kind is most often confused with a myasthenia gravis, and on what evidence are they told apart?" ], "whatItIsMadeOf": "content that has to be carried by something else", "physicalCharacter": [ "Does nothing on its own; everything it does, something else did to it.", "These come from the domain this entry sits in rather than from the entry itself, so treat them as a first guess about the whole domain applied to one thing." ], "whatCanBeDoneWithIt": [ "read it and act on what it says" ], "howItIsRecognised": [], "relatedModels": [ { "relation": "covers", "note": "Finer kinds folded into this entry because telling them apart needs a task that asks for it. Each is a model waiting to be split out when one does.", "targets": [ "myasthenic crisis", "neonatal myasthenia gravis", "adult-onset myasthenia gravis", "juvenile myasthenia gravis", "myasthenia, limb-girdle, autoimmune" ] } ], "standing": "Described in 65 Wikipedia languages, which measures how widely it is written about rather than how important or how common it is. 5 finer distinctions are held inside this entry as names rather than as separate models.", "structure": { "bundles": [ { "id": "identity-and-classification", "name": "Identity, naming and classification", "description": "How an agent tells one myasthenia gravis from another, and a myasthenia gravis from things that resemble it.", "rationale": "Recognition comes before every other claim. Without stable identity nothing else in the model can be trusted to be about the same thing twice.", "layers": [ { "id": "naming-and-identifiers", "name": "Names and identifiers", "description": "The names this thing goes by and the identifiers that survive translation and time.", "findings": [ { "id": "preferred-name-and-aliases", "name": "Preferred name, aliases and local names", "description": "Which name to use, which names mean the same thing, and which merely sound similar.", "questions": [ { "id": "preferred-name-and-aliases-q01", "text": "What identifies and describes the name of a myasthenia gravis, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "preferred-name-and-aliases-q02", "text": "Who or what asserted this about the name of a myasthenia gravis, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "preferred-name-and-aliases-q03", "text": "What may an agent decide or do once the name of a myasthenia gravis is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] }, { "id": "stable-identifiers", "name": "Stable identifiers and external keys", "description": "Identifiers that keep pointing at this kind of thing across systems and languages.", "questions": [ { "id": "stable-identifiers-q01", "text": "What identifies and describes an identifier for a myasthenia gravis, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "stable-identifiers-q02", "text": "Who or what asserted this about an identifier for a myasthenia gravis, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "stable-identifiers-q03", "text": "What may an agent decide or do once an identifier for a myasthenia gravis is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "classification-and-granularity", "name": "Classification and granularity", "description": "Where a myasthenia gravis sits among kinds, and how finely a task needs to cut it.", "findings": [ { "id": "kind-and-parents", "name": "Kind, parents and neighbouring kinds", "description": "The classes this thing belongs to and the ones it is next to.", "questions": [ { "id": "kind-and-parents-q01", "text": "What identifies and describes the kind of a myasthenia gravis, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "kind-and-parents-q02", "text": "Who or what asserted this about the kind of a myasthenia gravis, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "kind-and-parents-q03", "text": "What may an agent decide or do once the kind of a myasthenia gravis is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] }, { "id": "distinguishing-features", "name": "Distinguishing features", "description": "What separates a myasthenia gravis from the things most often confused with it.", "questions": [ { "id": "distinguishing-features-q01", "text": "What identifies and describes what distinguishes a myasthenia gravis, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "distinguishing-features-q02", "text": "Who or what asserted this about what distinguishes a myasthenia gravis, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "distinguishing-features-q03", "text": "What may an agent decide or do once what distinguishes a myasthenia gravis is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] }, { "id": "state-and-lifecycle", "name": "State and lifecycle", "description": "The states a myasthenia gravis passes through and the events that move it between them.", "rationale": "Most decisions about a thing depend on what state it is in now, which is a claim with a time on it, not a property.", "layers": [ { "id": "lifecycle-stages", "name": "Lifecycle stages", "description": "From coming into existence to ceasing to be one of these.", "findings": [ { "id": "stages-and-transitions", "name": "Stages and transitions", "description": "The stages worth naming and what moves a myasthenia gravis between them.", "questions": [ { "id": "stages-and-transitions-q01", "text": "What identifies and describes the lifecycle of a myasthenia gravis, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "stages-and-transitions-q02", "text": "Who or what asserted this about the lifecycle of a myasthenia gravis, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "stages-and-transitions-q03", "text": "What may an agent decide or do once the lifecycle of a myasthenia gravis is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "observations-and-status", "name": "Observations and current status", "description": "What is observed about a myasthenia gravis, how often and by whom.", "findings": [ { "id": "observation-record", "name": "Observation record", "description": "How an observation of a myasthenia gravis is recorded so that it can be superseded rather than overwritten.", "questions": [ { "id": "observation-record-q01", "text": "What identifies and describes an observation of a myasthenia gravis, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "observation-record-q02", "text": "Who or what asserted this about an observation of a myasthenia gravis, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "observation-record-q03", "text": "What may an agent decide or do once an observation of a myasthenia gravis is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] }, { "id": "content-and-access", "name": "Content, encoding and access", "description": "What a myasthenia gravis says, how it is encoded and who may read it.", "rationale": "An informational thing carries content that can be copied, versioned and withheld, none of which its physical carrier explains.", "layers": [ { "id": "content-and-encoding", "name": "Content and encoding", "description": "The content itself, its format and its language.", "findings": [ { "id": "content-and-format", "name": "Content, format and language", "description": "What a myasthenia gravis contains and in what form it is held.", "questions": [ { "id": "content-and-format-q01", "text": "What identifies and describes the content of a myasthenia gravis, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "content-and-format-q02", "text": "Who or what asserted this about the content of a myasthenia gravis, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "content-and-format-q03", "text": "What may an agent decide or do once the content of a myasthenia gravis is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "access-and-rights", "name": "Access, rights and retention", "description": "Who may read, copy or change it, and for how long it is kept.", "findings": [ { "id": "access-rules", "name": "Access rules and retention", "description": "The permissions attached to a myasthenia gravis and the period it survives.", "questions": [ { "id": "access-rules-q01", "text": "What identifies and describes access to a myasthenia gravis, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "access-rules-q02", "text": "Who or what asserted this about access to a myasthenia gravis, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "access-rules-q03", "text": "What may an agent decide or do once access to a myasthenia gravis is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] }, { "id": "subject-and-method", "name": "Subject matter and method", "description": "What myasthenia gravis studies and how it establishes anything.", "rationale": "A field is identified by its questions and its methods, and those are what distinguish it from the fields next to it.", "layers": [ { "id": "subject", "name": "Subject matter", "description": "The questions it takes as its own.", "findings": [ { "id": "subject-record", "name": "Questions and objects of study", "description": "What it is about, stated so a neighbouring field can be told apart.", "questions": [ { "id": "subject-record-q01", "text": "What questions and objects does myasthenia gravis take as its own?", "kind": "definition" }, { "id": "subject-record-q02", "text": "Which questions does it share with a neighbouring field, and who claims them?", "kind": "boundary" } ] } ] }, { "id": "method", "name": "Method and evidence", "description": "How claims are established and what counts as evidence.", "findings": [ { "id": "method-record", "name": "Methods and standards of evidence", "description": "The methods used and what they are taken to establish.", "questions": [ { "id": "method-record-q01", "text": "By what methods does myasthenia gravis establish claims, and what counts as sufficient evidence?", "kind": "provenance" }, { "id": "method-record-q02", "text": "What kind of claim can this field not settle, and where should an agent look instead?", "kind": "action" } ] } ] } ] }, { "id": "institutions-and-classification", "name": "Institutions and classification", "description": "Where myasthenia gravis is practised and how catalogues place it.", "rationale": "The institutional footprint is the evidence that a field exists as a field rather than as a topic.", "layers": [ { "id": "institutions", "name": "Institutional markers", "description": "Societies, journals, degrees and departments.", "findings": [ { "id": "institution-record", "name": "Bodies and venues", "description": "Where the field organises itself.", "questions": [ { "id": "institution-record-q01", "text": "Which societies, journals or degrees mark myasthenia gravis as an established field?", "kind": "provenance" }, { "id": "institution-record-q02", "text": "What would show that it is emerging or dissolving rather than established?", "kind": "boundary" } ] } ] }, { "id": "classification", "name": "Classification schemes", "description": "Where library and research classifications put it.", "findings": [ { "id": "classification-record", "name": "Codes and their disagreements", "description": "The classification codes that place it, and where they differ.", "questions": [ { "id": "classification-record-q01", "text": "Which classification schemes place myasthenia gravis, under what codes?", "kind": "definition" }, { "id": "classification-record-q02", "text": "Where do those schemes disagree about its scope?", "kind": "boundary" } ] } ] } ] }, { "id": "provenance-and-evidence", "name": "Provenance, evidence and time", "description": "Where every claim about a myasthenia gravis came from and when it held.", "rationale": "A claim without a source and a time cannot be superseded, only overwritten, and an agent that overwrites loses the ability to explain itself.", "layers": [ { "id": "source-and-authority", "name": "Source and authority", "description": "Who said it, on what evidence, and how strongly.", "findings": [ { "id": "claim-provenance", "name": "Claim provenance and confidence", "description": "The authority behind each claim about a myasthenia gravis and how confident it is.", "questions": [ { "id": "claim-provenance-q01", "text": "What identifies and describes a claim about a myasthenia gravis, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "claim-provenance-q02", "text": "Who or what asserted this about a claim about a myasthenia gravis, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "claim-provenance-q03", "text": "What may an agent decide or do once a claim about a myasthenia gravis is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "time-and-versions", "name": "Time, versions and supersession", "description": "When a claim was true, when it was learnt, and what replaced it.", "findings": [ { "id": "validity-and-supersession", "name": "Validity period and supersession", "description": "How an old claim about a myasthenia gravis is retired without being erased.", "questions": [ { "id": "validity-and-supersession-q01", "text": "What identifies and describes the validity of a claim about a myasthenia gravis, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "validity-and-supersession-q02", "text": "Who or what asserted this about the validity of a claim about a myasthenia gravis, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "validity-and-supersession-q03", "text": "What may an agent decide or do once the validity of a claim about a myasthenia gravis is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] } ] }, "statistics": { "bundles": 6, "layers": 12, "findings": 14, "questions": 38 } } } }